862: Reversing Cellular Senescence: GPX4, Ferroptosis, and Adaptive Senotherapeutics with Dr. Frederick Beddingfield

Are you fascinated by the molecular science of aging and senescence? In this episode of Beauty Bytes, I am joined by Dr. Frederick Beddingfield III, the CEO of Rubedo Life Sciences, a physician-scientist, and a former senior leader at Allergan. We focus on the cutting edge of longevity and how Rubedo is developing adaptive senotherapeutics to reverse cellular aging and extend healthspan. Dr. Beddingfield explains the science behind their lead drug, RLS 1496, which targets the enzyme glutathione peroxidase 4 (GPX4) to regulate ferroptosis, an iron-dependent cell death pathway. We discuss how this drug not only eliminates toxic senescent cells but also acts as a "redox reset" for aged cells, reducing their biological age by improving mitochondrial function and autophagy. We also explore their groundbreaking human clinical trials, which demonstrated a 50% reduction in precancerous actinic keratoses in just four weeks without causing skin irritation. Plus, Dr. Beddingfield shares his personal biohacking stack, including low-dose rapamycin, fisetin, and quercetin.

Guest Information:
Dr. Frederick Beddingfield III is the CEO of Rubedo Life Sciences. You can learn more about their clinical trials at rubedolifesciences.com or follow him on Instagram and LinkedIn at @FrederickBeddingfield.